Certified Duchenne Care Center

PPMD Designates Lurie Children's a Certified Duchenne Care Center

PPMD is excited to announce our 14th Certified Duchenne Care Center -- Ann & Robert H. Lurie Children’s Hospital of Chicago!
February 16, 2017 | Learn more 

February 22

Upcoming Webinar 2/22: NS Pharma's Exon 53 Skipping Program

Join PPMD and NS Pharma as we host a webinar Wednesday, February 22 at 1:00 PM EST to to provide an update on trial recruitment for NS Pharma's Exon 53 Skipping Program.
February 16, 2017 | Learn more 

News Update

PPMD Recommends Marathon Convene Broad Array of Duchenne Stakeholders to Discuss Re-evaluation of Deflazacort Pricing

In light of the pause in commercialization of EMFLAZA™ (deflazacort) by Marathon Pharmaceuticals earlier this week, PPMD recommends that Marathon seek input from a broad array of stakeholders including Duchenne clinicians, health insurance plans, pharmacy benefit managers, and Duchenne advocacy groups.
February 15, 2017 | Learn more 

News Update - eNews

End Duchenne eNews: Raising Our Voices for Every Single One

Catch up on the latest research and community updates in this month's End Duchenne eNews.
February 15, 2017 | Learn more 

News Update - Action Alert

Urge Congress to Protect Duchenne Community's Healthcare Priorities

This week, PPMD advocates from across the country are storming Capitol Hill to ensure legislators make Duchenne and rare disease a priority. This year’s agenda includes urging Congress NOT to repeal the Patient Protection and Affordable Care Act until there is a guarantee that people with Duchenne will continue to have access to equal or better coverage. Please take a moment today to tell Congress why this matters so much to our community!
February 14, 2017 | Take Action 

News Update

Marathon Pharmaceuticals Update on EMFLAZA™ (deflazacort)

Marathon has announced that they will pause the commercialization of their recently FDA-approved steroid EMFLAZA™ (deflazacort). This pause will allow Marathon to consider the feedback they have received from the community since last week’s announcement regarding pricing and potential for combining this therapy with other approved drugs in the future. Marathon has assured families that during this pause, access to deflazacort will not be disrupted.
February 13, 2017 | Learn more 

News Update

Deflazacort Approved in the U.S. for Duchenne

Today, the FDA approved EMFLAZA™ (deflazacort) for Duchenne. This is the first approval of a steroid for Duchenne and a therapy that applies to people with Duchenne 5 years of age and older, regardless of genetic mutation. Representatives from Marathon Pharmaceuticals will be joining us for a webinar Friday, February 10th at 12 PM EST to provide information about EMFLAZA’s FDA-approved label, patient support services, and access to this medication. 
February 9, 2017 | Learn more 

News Update

PPMD to Host Forum on Access to Emerging Therapies

PPMD is hosting the Access to Emerging Therapies Forum on February 13th, 2017 for our patient community and relevant stakeholders. Our presenters include policy experts who will present on the various points on the access continuum.
February 7, 2017 | Learn more 

News Update

[Webinar Recording] MoveDMD Trial: Catabasis Provides Update

The Catabasis team recently joined us to discuss what they have learned from Part B of the MoveDMD® trial of edasalonexent (CAT-1004) in Duchenne and what comes next in the MoveDMD program.
February 6, 2017 | Learn more 

News Update

[Webinar Recording] Mission DMD: FibroGen’s Anti-Fibrosis Program

FibroGen recently joined us for a webinar discussion on the company's investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is currently being conducted to investigate Pamrevlumab in Duchenne.
February 3, 2017 | Learn more 

News Update

Registration for our 2018 Walt Disney World Marathon Weekend team is now open!

2018 marks the 25th anniversary of the Full Marathon, with lots of other fun race distances available too. It's the biggest and best marathon weekend of the year for our Run For Our Sons team, and spots are filling up fast. Don't miss out on this magical weekend!
February 2, 2017 | Learn more 

News Update

PPMD’s Duchenne Drug Development Roundtable: Bringing Industry Together to Accelerate Research

Today is the first of PPMD's Duchenne Drug Development Roundtable (DDDR) three-meeting series to address clinical trial challenges and opportunities within our Duchenne space.
February 1, 2017 | Learn more 

News Update

PPMD Awards $250,000 Grant to UT Southwestern Medical Center to Explore CRISPR/Cas9 Technology

This grant, part of PPMD’s Gene Transfer Initiative, will support Dr. Olson’s ongoing study of CRISPR/Cas9 technology as a potential treatment for Duchenne
January 30, 2017 | Learn more 

News Update

[Webinar Recording] Summit's Utrophin Modulation Program

Summit joined us earlier this week for an educational webinar on utrophin modulation, an approach for Duchenne that has the potential to treat all patients.
January 27, 2017 | Learn more 

News Update

[Webinar Recording] Vamorolone (VBP15) Clinical Trials in Duchenne

ReveraGen BioPharma CEO Dr. Eric Hoffman joined us earlier this week for a webinar discussion on vamorolone (VBP15) clinical trials in Duchenne. 
January 20, 2017 | Learn more 

Certified Duchenne Care Center

PPMD Designates Yale New Haven Children's Hospital a Certified Duchenne Care Center

PPMD is excited to announce our 13th Certified Duchenne Care Center (CDCC) the Yale New Haven Children's Hospital's Muscular Dystrophy Program!
January 19, 2017 | Learn more 

News Update

PPMD Awards $600,000 Grant to NJIT & Talem for Next Phase of Upper Extremity Exoskeleton

PPMD has awarded a $600,000 grant to the New Jersey Institute of Technology (NJIT) and Talem Technologies as part of our ongoing exploration of robotic technology to assist people living with Duchenne.
January 18, 2017 | Learn more 

News Update

New Resource to Help Navigate EXONDYS 51 Access

Dr. Craig McDonald of UC Davis has shared data and an accompanying presentation to serve as a resource for families who have received an EXONDYS 51 denial from their insurance company and are working to appeal the decision. You should insist that both your clinician and insurance company review this data and presentation.
January 13, 2017 | Learn more 

News Update

New Research & Clinical Trial Tools on DuchenneConnect

We are excited to announce three new tools now available on PPMD's DuchenneConnect! These tools are meant to help you in your journey as you gather information around potential research studies and potential new exon skipping therapies.
January 12, 2017 | Learn more 

News Update

PPMD Awards $2.2 Million Grant to Explore Gene Therapy in Duchenne

PPMD has announced a $2.2 million dollar grant to Dr. Jerry Mendell, Dr. Louise Rodino-Klapac (co-PI), and Nationwide Children’s Hospital. This grant is the first project of a new Gene Transfer Initiative PPMD is launching this month that will include the work Dr. Mendell and Dr. Rodino-Klapac are doing, as well as a deeper exploration of CRISPR/Cas9 technology as a potential therapeutic approach to treating Duchenne.
January 6, 2017 | Learn more 

 
Connect with PPMD
Facebook YouTube Twitter

Quick Links
How We Help



Our family-centered approach is at the heart of everything we do. Learn more.

Quick Links

More Links

PPMD Sites